| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | 17-AAG | FIMM | pan-cancer | AAC | -0.055 | 0.8 |
| mRNA | BMS-754807 | GDSC1000 | pan-cancer | AAC | -0.01 | 0.8 |
| mRNA | EX-527 | GDSC1000 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | BRD4132 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | LRRK2-IN-1 | CTRPv2 | pan-cancer | AAC | 0.011 | 0.8 |
| mRNA | CIL55 | CTRPv2 | pan-cancer | AAC | -0.018 | 0.8 |
| mRNA | selumetinib:navitoclax (8:1 mol/mol) | CTRPv2 | pan-cancer | AAC | -0.011 | 0.8 |
| mRNA | MK-0752 | CTRPv2 | pan-cancer | AAC | 0.012 | 0.8 |
| mRNA | Bortezomib | gCSI | pan-cancer | AAC | -0.018 | 0.8 |
| mRNA | PFI-1 | GDSC1000 | pan-cancer | AAC | -0.0097 | 0.8 |